RHAPSODY

The project aims to identify new molecular biomarkers of pre-diabetes and T2D development and to define a molecular taxonomy of type 2 diabetes mellitus.

Aim project: RHAPSODY is an EU Innovative Medicine Initiative (IMI) funded consortium comprising 26 partners across Europe, including academic partners and pharmaceutical industry. The project aims to identify new molecular biomarkers of pre-diabetes and T2D development and to define a molecular taxonomy of type 2 diabetes mellitus. Newly identified biomarkers will improve monitoring progression of the prediabetic state to T2D and allow improved patient stratification. To achieve this, it combines existing data from multiple large prospective (pre-) diabetic cohorts across Europe. Genetics, genomics, clinical, and biochemical data is stored in a  federated database that allows modeling of the data at a consortium-wide level.

€18.000.00,00

Role of research group in this project: Within RHAPSODY clinical and omics data of the Hoorn Diabetes Care System (DCS) cohort will be shared via a federated node system of which on is hosted by the VUmc. The federated nodes will be used to perform joint analyses on the three diabetes cohorts used by the consortium: DCS, GoDarts (Dundee, UK) and ANDIS (Lund, Sweden).

Click to read more (external website)